John Lansing's Trending123
John Lansing's Trending123
Username: Password: Login
Trade Talk E-Letter Products & Services Trading Tools Portfolios Members Home

Stock Sectors

(Click sector to view stock chart)

Diagnostic Substances

Stock Charts
(Click stock symbol to view stock chart, Support, Resistance, Pivot, Option chain, Volume, P/E, High, Low, Close, Market Cap, Average Volume, Dividend, % Change, $ Change, R1, R2, S1, S2, Previous Close, RSI - MACD - Williams %R - Stochastics - PPO, CMF, ADX, Aroon and more.......)


Myriad Genetics, Inc., a biopharmaceutical company, engages in the development and marketing of therapeutic and molecular diagnostic products. Its lead drug candidate is Flurizan, a therapeutic drug for the treatment of Alzheimer's disease, which completed a Phase II human clinical trial in patients with mild to moderate Alzheimer's disease. Flurizan is also in a Phase IIb human clinical trial for the treatment of patients with premetastatic prostate cancer. The company's other products under development include MPC-6827, a small-molecule drug candidate that inhibits tubulin, an important protein involved in cell division for treatment of advanced solid tumors or metastatic brain tumors; MPC-2130, a novel apoptosis inducing small molecule for the treatment of metastatic tumors or blood cancers, as well as refractory cancer, ovarian cancer, and prostate cancer; and MPI-49839, a viral budding inhibitor for the treatment of AIDS. It also offers various predictive medicine products, including BRACAnalysis, which assesses a woman's risk of developing breast and ovarian cancer; COLARIS and COLARIS AP, which determine a person's risk of developing colon cancer; and MELARIS, which assesses a person's risk of developing malignant melanoma. Myriad Genetics has strategic alliances with Abbott Laboratories and E.I. du Pont de Nemours and Company. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.


Meridian Bioscience, Inc. operates as an integrated research, development, manufacturing, marketing, and sales organization in the field of life science. It develops, manufactures, and distributes diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases; and bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers, as well as provides contract manufacturing service of proteins and other biologicals for use by biopharmaceutical and biotechnology companies that are engaged in research for new drugs and vaccines. The company's product technologies include enzyme immunoassay, immunofluorescence, particle agglutination/aggregation, immunodiffusion, complement fixation, and chemical stains. It markets its products to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, and diagnostics manufacturers in approximately 60 countries worldwide, through direct sales force and independent distributors. The company was founded in 1976 and is based in Cincinnati, Ohio.


Dade Behring Holdings, Inc. engages in the manufacture and distribution of diagnostics products and services to clinical laboratories worldwide. It provides medical diagnostic instruments, reagents and consumables, and maintenance services. The company has four core product lines comprising chemistry/immunochemistry, hemostasis (coagulation), microbiology, and infectious disease diagnostics. Its chemistry/immunochemistry product line consists of routine chemistry/immunochemistry, cardiac, plasma proteins, and drugs of abuse testing/therapeutic drug monitoring instruments, which include Dimension RxL, Stratus CS, Plasma Proteins, and Syva. These products are used to detect and measure substances that may be found in patients' blood, urine, or tissue samples. The hemostasis products mainly measure patients' ability to form and dissolve blood clots and is generally used before and during surgical procedures or for monitoring coagulation disorders, such as hemophilia. Dade Behring's microbiology products (MicroScan) are used to identify infection-causing bacteria and the minimum dose of antibiotics necessary to treat the infection. Its infectious disease diagnostics systems are primarily used for virology testing, including screening for infections, such as hepatitis, HIV, and sexually transmitted diseases. Dade Behring Holdings is headquartered in Deerfield, Illinois.


Neogen Corporation engages in the development, manufacture, and sale of various products for food safety testing and animal health applications. The company operates in two segments, Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect dangerous and unintended substances in food and animal feed, such as foodborne pathogens, food allergens, natural toxins, genetic modifications, ruminant by-products, drug residue, pesticide residue, disease infections, and general sanitation concerns. The Animal Safety segment produces and markets pharmaceuticals, vaccines, veterinary instruments, topicals, and diagnostic products for the detection of abused and therapeutic drugs in animals and animal products. It also produces and markets rodenticides for the control of rats and mice in and around agricultural, food production, and other facilities. The company, through its direct sales staff and distributors, sells its products primarily in the United States, South and Central America, Canada, Asia, and Europe. Neogen was formed in 1981 and is headquartered in Lansing, Michigan.


Orchid Cellmark, Inc. provides deoxyribonucleic acid (DNA) testing services that generate genetic profile information by analyzing an organism's unique genetic identity. The company focuses on DNA testing for human identity, as well as for animal and agricultural applications. In the human identity area, it provides DNA testing services for forensic, family relationship, and security applications. In the animal and agriculture field, the company provides DNA testing services for food safety and selective trait breeding. Orchid Cellmark conducts forensic DNA testing primarily for government agencies; family relationship testing services to both government agencies and private individuals; security DNA testing services to government agencies, commercial companies, and private individuals; and animal and agriculture DNA testing services for government agencies and commercial companies. It markets its services to customers based in North America and Europe. The company was organized in 1995 and was formerly known as Orchid Biocomputer, Inc. and changed its name to Orchid Biosciences, Inc. Subsequently, it changed it name to Orchid Cellmark, Inc. in June 2005. Orchid Cellmark is headquartered in Princeton, New Jersey.


Avalon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of cancer therapeutics using AvalonRx technology in the United States. It offers AVN944, a Phase I clinical development product for the treatment of hematologic and solid tumor cancers. The company also engages in preclinical programs to develop inhibitors of the Beta-catenin and Aurora pathways, and discovery programs for Survivin and Myc pathway inhibitors. It has collaborations with Merck & Co., Inc., MedImmune, Inc., Novartis Institutes for Biomedical Research, Inc., Medarex, Inc., and ChemDiv, Inc. Avalon Pharmaceuticals was founded in 1999 and is headquartered in Germantown, Maryland.


Icagen, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered small molecule drugs that modulate ion channel targets. The company's four advanced programs include ICA-17043, an inhibitor of the Gardos channel, for the chronic treatment of sickle cell disease, which is in Phase III clinical trials; a lead compounds for epilepsy and neuropathic pain, which is under preclinical studies; a compound for atrial fibrillation, which is being developed by its collaborator Bristol-Myers Squibb Company and is in phase I clinical trials; and a compound for dementia, including Alzheimer's disease, which is being developed by its collaborator Yamanouchi Pharmaceutical Co., Ltd. and is undergoing advanced preclinical testing. In addition, it conducts drug discovery programs focused on new therapeutics for pain disorders, inflammatory disorders, and glaucoma. Icagen has collaboration and copromotion agreements with McNeil Consumer & Specialty Pharmaceuticals Division of McNeil-PPC, Inc. relating to the development and commercialization of ICA-17043; and with Abbott Laboratories to discover, develop, and market compounds that act on specified ion channel targets for the treatment of neuropathic pain and with application in urology, including the treatment of urinary incontinence. The company was co-founded by P. Kay Wagoner and H. Jefferson Leighton. It was incorporated in 1992 and is based in Durham, North Carolina.


AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The company markets Feridex I.V., a liver contrast agent; and GastroMARK, an oral contrast agent for delineating the bowel in magnetic resonance imaging (MRI) primarily in Europe and the United States. Its product candidate, Ferumoxytol, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients; and Combidex, an investigational functional molecular imaging agent, consists of iron oxide nanoparticles for use in conjunction with MRI to aid in the differentiation of cancerous from normal lymph nodes. The company was founded in 1981 as Advanced Magnetics, Inc. and changed its name to AMAG Pharmaceuticals, Inc. in July 2007. AMAG Pharmaceuticals is based in Cambridge, Massachusetts.


Quidel Corporation engages in the development, manufacture, and marketing of point-of-care (POC) rapid diagnostic solutions for infectious diseases and reproductive health. Its POC and diagnostic tests include QuickVue, QuickVue+, QuickVue Advance, RapidVue, BlueTest, and Metra. These products provide diagnostic information for acute and chronic conditions that affect women and their family's health. The company offers POC diagnostics for infectious diseases, such as Influenza, Group A Strep, Helicobacter pylori, and Mononucleosis; Reproductive Health, which include Pregnancy, Chlamydia, and Bacterial Vaginosis; and Bone Health and Oncology. Quidel's products under development include Strep A web, respiratory syncitial virus test, LTF technology platforms, and QuickVue advance pH and amines test. The company incorporates immunoassay, enzymology, biochemistry, and microbiology technology into its diagnostic products. It markets its products to its customers through a network of distributors supported by a direct sales force in the United States, and through distributors and sales agents primarily in Japan, Europe, and Latin America. Quidel sells its products to professionals for use in physician offices, hospitals, clinical laboratories, and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, California.


Immucor, Inc. engages in the development, manufacture, and marketing of immunological diagnostic medical products primarily in North America and Europe. It offers a line of reagents and automated systems that are used by hospitals, clinical laboratories, and blood banks in various tests performed to detect and identify various properties of cell and serum components of human blood. The company's reagent product lines include ABO blood grouping and Rh blood typing reagents, anti-human globulin serums, reagent red blood cells, rare serums, antibody potentiators, quality control systems, monoclonal antibody-based reagents, technical proficiency systems, and fetal bleed screen kit, as well as Capture-P, Capture-R, Capture-CMV, Capture-S, and Capture-R Select reagents. These reagents are used in tests performed prior to blood transfusion in determining the blood group and type of patients' and donors' blood; detection and identification of blood group antibodies; detection of platelet antibodies; and paternity testing. Immucor's blood bank automation products include ABS2000, an automated blood bank system; ROSYS Plato, a microplate liquid handler and sample processor; DIAS PLUS and GALILEO, which are high volume microplate processors; and Multireader Plus, a spectra photometric microtitration plate reader. These blood bank automation products enable technologist to perform blood compatibility tests. The company also distributes laboratory equipment designed to automate certain blood testing procedures. It sells its products through direct sales personnel, sales agents, and distributors worldwide. Immucor has a joint venture, known as Immucor-Kainos, Inc., with Kainos Laboratories, Inc. for the distribution of its products in Japan; and a development agreement with Inamed Corporation for the production of human collagen mesh. Immucor was founded in 1982 and is headquartered in Norcross, Georgia.


Nymox Pharmaceutical Corporation, through its subsidiaries, engages in the research and development of products for the diagnosis and treatment of Alzheimer's disease. The company markets AlzheimAlert, a urinary test that helps physicians in the diagnosis of Alzheimer's disease. It also markets NicAlert and TobacAlert tests that use urine or saliva to detect the use of tobacco products. In addition, Nymox develops therapeutics for the treatment of Alzheimer's disease; treatments for benign prostate hyperplasia; and anti-bacterial agents for the treatment of urinary tract and other bacterial infections in humans, including a treatment for E. coli O157:H7 bacterial contamination in meat and other food and drink products. The company was founded by Paul Averback in 1989 and is based in St. Laurent, Canada.


ISTA Pharmaceuticals, Inc. engages in the development and commercialization of products for serious diseases and conditions of the eye. Its product pipeline includes Vitrase, a proprietary formulation of ovine hyaluronidase for the treatment of vitreous hemorrhage, for use as a spreading agent to facilitate the absorption and dispersion of other injected drugs, as well as for the treatment of diabetic retinopathy; Istalol, a topical solution of timolol, for the treatment of glaucoma, a chronic disease that gradually reduces eyesight; Xibrom, a topical nonsteroidal anti-inflammatory compound for the treatment of ocular inflammation; Ecabit sodium for dry eye syndrome;and Caprogel, a topical gel formulation of aminocaproic acid, for the treatment of hyphema. ISTA Pharmaceuticals has collaborations with Allergan, Inc.; Otsuka Pharmaceutical Co., Ltd.; Senju Pharmaceuticals Co., Ltd.; and Eastern Virginia Medical School. The company was founded in 1992 as Advanced Corneal Systems, Inc. and changed its name to ISTA Pharmaceuticals, Inc. in 2000. ISTA Pharmaceuticals is headquartered in Irvine, California.


SurModics, Inc. provides surface modification and drug delivery technologies for the healthcare industry. It operates in three segments: the Drug Delivery, the Hydrophilic and Other, and the Diagnostics. The Drug Delivery segment contains the Drug Delivery business unit, which offers technologies to site specific delivery of drugs; and the Ophthalmology division, which offers treatment for eye diseases, such as age-related macular degeneration and diabetic macular edema. The Hydrophilic and Other segment contains the Hydrophilic Technologies business unit, which focuses on enhancing medical devices with lubricious coatings; Regenerative Technologies business unit, which develops platforms to augment or replace tissue/organ function or to modify medical devices to facilitate tissue/organ recovery through natural repair mechanisms; and Orthopedics business unit, which offers solutions for orthopedics patients. The Diagnostics segment contains the Diagnostics and Drug Discovery business unit, which includes genomics slide technologies, stabilization products for immunoassay diagnostics tests, in vitro diagnostic format technology, and develops synthetic cell culture products. It offers PhotoLink surface modification coatings and drug delivery polymer matrices. The company provides polymer coatings for drug-eluting stents, lubricious coatings, and cell encapsulation technology for islet cell implantation. It also offers chemical reagents used in the coating process, as well as coated glass slides and stabilization products. The company serves medical device, pharmaceutical, and life science companies, as well as development stage companies. Its technologies and products are marketed through direct sales force worldwide. The company, formerly known as BSI Corporation, was founded in 1979 and changed its name to SurModics, Inc. in 1997. SurModics is headquartered in Eden Prairie, Minnesota.


IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of veterinary, food, and water testing products and related services worldwide. The company operates in three segments: Companion Animal Group (CAG), Water Quality Products (Water), and the Food Diagnostics Group (FDG). The CAG segment offers single-use, hand-held test kits that allow test results for various companion animal diseases and health conditions. It also provides instrument systems, including blood and urine chemistry analyzer, and hematology analyzers, as well as offers commercial veterinary laboratory and consulting services. The Water segment develops, designs, manufactures, and distributes products to detect contaminants in water. Its Colilert, Colilert-18, and Colisure tests detect coli-forms and E. coli in water. These water tests are used by government laboratories, water utilities, and private certified laboratories. This segment's products also comprise Enterolert, which detects enterococci in drinking and recreational waters; and Quanti-Tray, which provide users measurements of microbial contamination. FDG manufactures and distributes products to detect disease and contaminants in production animals and food. It sells diagnostic tests and related instrumentation and software that are used to detect a range of diseases and to monitor health status in production animals. The production animal products are purchased primarily by government laboratories, and poultry and swine producers. In addition, this segment sells SNAP beta-lactam, which is used in testing antibiotic residue in milk, to milk producers and processors. The company markets, sells, and services its products through its sales force, as well as through independent distributors and resellers. IDEXX was incorporated in 1983 and is based in Westbrook, Maine.


E-Z-EM, Inc. engages in the development, manufacture, and marketing of medical products used by radiologists, gastroenterologists, and speech language pathologists primarily in screening for, and diagnosing diseases and disorders of the gastrointestinal (GI) tract. The company provides products for use in colorectal cancer screening, evaluation of swallowing disorders, and testing for other diseases and disorders of the GI system. E-Z-EM offers VoLumen, a low density barium sulfate suspension for use as an oral contrast in multidetector computed tomography (CT) and positron emission tomography/CT studies. The company also offers Empower line of electromechanical injectors to deliver a volume of iodine-based contrast media into patients to visualize the vascular structure of the circulatory system, as well as organs in the thoracic, abdominal, and pelvic regions. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents, and a carbon dioxide colon insufflation system. The company also serves as a third-party contract manufacturer. E-Z-EM manufactures and markets reactive skin decontamination lotion (RSDL) for first-responder organizations and military services in many countries. RSDL is a liquid skin decontaminant that neutralizes a spectrum of chemical warfare and toxic agents. The company distributes its products worldwide through its sales force and distributors. E-Z-EM was founded in 1961 by Howard Stern and Phillip Meyers. The company is headquartered in Lake Success, New York.


Abaxis, Inc. engages in the development, manufacture, and marketing of portable blood analysis systems for use in veterinary or human patient-care setting to provide clinicians with blood constituent measurements. Its primary product is a blood analysis system, consisting of a 6.9 kilogram analyzer and a series of single-use plastic discs, called reagent discs, containing chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system performs multiple routine tests on whole blood, serum, or plasma samples. It markets this system for veterinary use under the VetScan name and in the human medical market under the Piccolo name. Abaxis sells this system either directly or through distributors in North America, Europe, Asia, and Latin America. The company was co-founded by Vladimir E. Ostoich in 1989 and is headquartered in Union City, California.


Pressure BioSciences, Inc. (PBI), an early-stage company, focuses on the development of a technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between various levels to control bio-molecular interactions. The company, utilizing its PCT technology, researches, develops, and commercializes products for the control of bio-molecular interactions. Its products primarily include Barocycler NEP 2017, an instrument that is designed as a front-end sample preparation tool for genomic and proteomic systems; Barocycler NEP 3229, which is a lightweight, portable instrument designed to fit on a laboratory bench top, inside a biological safety cabinet, or on the shelf of a cold room; and PULSE tubes that transmit the power of PCT from the Barocycler instruments to the sample. PBI holds 13 US and 4 foreign patents covering multiple applications of PCT in the life sciences field, including areas, such as genomic and proteomic sample preparation, pathogen inactivation, control of enzymes, immunodiagnostics, and protein purification. It also owns a 30% investment in Source Scientific, LLC, which is an instrumentation company that develops and manufactures PBI's PCT equipment. In addition, the company owns a passive investment in V.I. Technologies, Inc., formerly Panacos Pharmaceuticals, Inc., which is an antiviral drug discovery and development company. Pressure BioSciences was founded by Richard T. Schumacher in 1978. The company was formerly known as Boston Biomedica, Inc. (BBI) and changed its name to Pressure BioSciences, Inc. in September 2004, following the sale of assets and selected liabilities of its BBI Diagnostics and BBI Biotech divisions to SeraCare Life Sciences, Inc. Pressure BioSciences is headquartered in West Bridgewater, Massachusetts.


Trinity Biotech Plc engages in the development, manufacture, and marketing of diagnostic test kits used for the clinical laboratory and point-of-care segments of the diagnostic market. Its test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune disorders. The company also provides raw materials to the life sciences industry. Trinity Biotech sells its products through its sales force and a network of distributors and strategic partners in the United States and internationally. The company was co-founded by Ronan O'Caoimh and Denis R. Burger in 1992. Trinity Biotech is headquartered in Bray, Ireland.


Genelabs Technologies, Inc. engages in the discovery and development of pharmaceutical products to improve human health. It is developing Prestara (prasterone), an investigational drug for women with systemic lupus erythematosus. The company also pursues drug discovery of novel antiviral compounds for treatment of hepatitis C virus infections and advances preclinical development of compounds in this program. Genelabs Technologies has strategic collaborations with Watson Pharmaceuticals, Inc. and Tanabe Seiyaku Co., Ltd. for the development and commercialization of its investigational new drug. The company was founded in 1983 and is headquartered in Redwood City, California.


Poniard Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of cancer therapy products in the United States. Its lead product is Picoplatin, a platinum-based cancer therapy, designed to overcome platinum resistance in the treatment of solid tumors. Picoplatin is in Phase II clinical trails in small cell lung cancer and is in Phase I/II trials for colorectal and hormone-refractory prostate cancers. The company has a collaboration agreement with The Scripps Research Institute on the discovery of novel, small-molecule, and multi-targeted protein kinase inhibitors and focal adhesion kinase inhibitors as therapeutic agents, including for the treatment of cancer. Poniard Pharmaceuticals was founded in 1984. It was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in 2006. The company is headquartered in South San Francisco, California.


Avigen, Inc., a development stage company, focuses on the acquisition, development, and commercialization of therapeutics to treat serious disorders, primarily for neurological conditions. It acquires or in-license later stage drug development candidates. Avigen was established in 1992 and is headquartered in Alameda, California.


SCOLR Pharma, Inc., a drug delivery company, engages in the development and formulation of over-the-counter products, prescription drugs, and nutraceutical products that use its patented controlled delivery technology (CDT). It uses CDT platform to develop products and license technology to pharmaceutical and nutritional product companies. The company's products include Ibuprofen, for analgesic; Pseudoephedrine, a drug for decongestion; Raloxifene, for osteoporosis; Niacin, for cardiac; and Tramadol, an analgesic drug. SCOLR has strategic alliance with Archer-Daniels-Midland Company for the development of certain CDT-based dietary supplement and nutraceutical products. The company was incorporated in 1994 under the name Caddy Systems, Inc. and changed its name to Nutraceutix, Inc. in 1995. Further, it changed name to SCOLR, Inc. in 2002 and to SCOLR Pharma, Inc. in 2004. SCOLR is headquartered in Bellevue, Washington.


ImmuCell Corporation engages in the research and development, manufacture, and sale of diagnostic tests and products for therapeutic and preventive use against certain infectious diseases in animals and humans. It offers animal health products, including First Defense, a scours preventive product, which is manufactured from cows' colostrum using the company's vaccine and milk protein purification technologies; Wipe Out Dairy Wipes, MASTiK, and California Mastitis Test, which aid in the detection and treatment of mastitis caused by bacterial infections; Rapid Johne's Test, a test that identifies cattle with symptomatic Johne's disease; and rpt, a milk progesterone test used by dairy producers to monitor the reproductive status of their cows. The company is also developing Crypto-Scan water diagnostic test for preventing cryptosporidium parvum infections in humans, as well as Mast Out, an intramammary infusion product, as an alternative to traditional antibiotics used in the treatment of mastitis in lactating dairy cows. The company serves veterinarians and producers in the dairy and beef industries in the United States. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.


Human Genome Sciences, Inc. operates as a biopharmaceutical company with a pipeline of novel protein and antibody drugs. The company's drugs in clinical development include LymphoStat-BTM for the treatment of lupus and rheumatoid arthritis; AlbuferonTM for the treatment of chronic hepatitis C; HGS-ETR1, HGS-ETR2, HGS-TR2J for the treatment of solid and hematopoietic cancers; CCR5 mAb for the treatment of HIV/ AIDS; and ABthraxTM for the treatment of anthrax infection. It has various strategic partners, including GlaxoSmithKline, Takeda, Schering-Plough, Sanofi-Synthelabo, Merck KGaA, Transgene, MedImmune, Inc., and Pharmacia & Upjohn. Human Genome Sciences was founded in 1992 and is headquartered in Rockville, Maryland.


Immunomedics, Inc. engages in the development, manufacture, and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer, autoimmune, and other diseases. The company offers its CEA-Scan, a diagnostic imaging agent used for the detection of colorectal cancers, in the United States and Canada, as well as in Europe. It offers its LeukoScan, a diagnostic product used for the detection of bone infections, in Europe and Australia. Immunomedics' therapeutic product candidates primarily comprised epratuzumab, which completed certain Phase II clinical trials for the treatment of nonHodgkin's lymphoma, as well as labetuzumab, which was in Phase I/II clinical trials for the treatment of certain solid tumors and hematologic malignancies, as of June 30, 2004. The company was founded by David M. Goldenberg. Immunomedics was incorporated in 1982 and is headquartered in Morris Plains, New Jersey.


TorreyPines Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat diseases and disorders of the central nervous system. It focuses on two therapeutic areas, such as chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia (CISA) and Alzheimer's disease. The company's product candidates in clinical trials include tezampanel, a Phase IIb clinical trial product, and NGX426, a Phase I clinical trial product for the treatment of migraine. It also develops NGX267, a Phase I clinical trial product for the treatment of CISA. In addition, TorreyPines Therapeutics develops various products for the treatment of Alzheimer's disease, including NGX292, Bisnorcymserine, and NGX555, which are in preclinical stages; phenserine, which has completed phase III clinical trials; and Posiphen, which is in phase I clinical trials. The company has a strategic alliance with Eisai Co., Ltd. TorreyPines Therapeutics is based in La Jolla, California.


Monogram Biosciences, Inc., a life sciences company, engages in the development and commercialization of molecular diagnostic products focusing on infectious diseases, cancer, and other diseases. The company's products for infectious diseases include PhenoSense HIV that directly and quantitatively measures resistance of a patient's HIV to anti-viral drugs; GeneSeq HIV for examining and evaluating the genetic sequences of a patient's HIV; PhenoSense GT; Replication Capacity HIV that measures viral fitness or the ability of a virus to reproduce and infect new cells; PhenoScreen for the identification of potential clinical drug candidates; and PhenoSense HIV Entry that measures resistance of a patient's HIV to entry inhibitors. It also offers GeneSeq HIV Entry, which examines and evaluates the genetic sequences of a patient's HIV for evidence of resistance to entry inhibitors; Co-Receptor Tropism that identifies the co-receptor the patient's virus uses to enter cells; PhenoSense and GeneSeq HIV Integrase that measures HIV resistance to integrase inhibitors for use in research and drug development; and PhenoSense HIV Antibody Neutralization for use in vaccine development programs. In addition, the company offers PhenoSense HCV and GeneSeq HCV assays for use in their drug discovery and development programs by pharmaceutical companies. Monogram Biosciences also provides eTag technology, an assay platform for analyzing very small amounts of tumor samples recovered and prepared in various methods, for use in cancer therapeutics. The company offers its products to physicians and pharmaceutical customers through a direct and indirect sales organization. Monogram Biosciences, formerly known as ViroLogic, Inc., was founded in 1995. It changed its name to Monogram Biosciences, Inc. in 2005. Monogram Biosciences is based in South San Francisco, California.


Rosetta Genomics, Ltd., a biotechnology company, develops microRNA-based diagnostic and therapeutic products. MicroRNAs are naturally expressed or produced using instructions encoded in DNA, and could be used in regulating protein production. The company, using its intellectual property, collaborative relationships, and microRNAs, has initiated programs to develop microRNA-based diagnostic and therapeutic products for various cancers and infectious diseases. It primarily focuses on prostate, lung, colorectal, breast, and bladder cancers. Rosetta Genomics is also developing a diagnostic test to identify the origin of the primary tumor in metastatic cancers of unknown primary site. In addition, it is collaborating with others on the development of microRNA-based therapeutic products for the treatment of liver cancer and infectious diseases. The company has collaboration and license agreements with Asuragen, Inc.; Isis Pharmaceuticals, Inc.; Hadasit Medical Research Services and Development, Ltd.; U.S. Genomics, Inc.; The Rockefeller University; Max Planck Innovation GmbH; Johns Hopkins University; Columbia University; and Tel Hashomer Medical Research Infrastructure and Services, Ltd. Rosetta Genomics was founded in 2000 and is based in Rehovot, Israel.


Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions in the United States. It is conducting a Phase I clinical trial of its lead product candidate, IPI-504, a novel, proprietary small molecule inhibitor of Hsp90, in patients with Gleevec-refractory gastrointestinal stromal tumors, as well as a Phase I/II clinical trial in patients with advanced non-small cell lung cancer. The company is also analyzing data from its Phase I clinical trial of IPI-504 in patients with refractory multiple myeloma. In addition, it focuses on the development and commercialization of cancer drugs targeting the Hedgehog pathway, as well as on the identification of small molecule compounds that inhibit the Bcl-2 family of proteins. The company has a product development and commercialization agreement with MedImmune, Inc. to jointly develop and commercialize novel small molecule cancer drugs, including IPI-504, targeting Hsp90, as well as those targeting the Hedgehog pathway; and with Novartis Institutes of BioMedical Research to discover, develop, and commercialize drugs targeting the Bcl family of proteins. Infinity Pharmaceuticals is based in Cambridge, Massachusetts.


EpiCept Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceutical products for the treatment of cancer and pain. It offers Ceplene, which is used for the treatment of acute myeloid leukemia. The company also provides EpiCept NP-1, a late-stage pain product candidate, for relief from the pain of peripheral neuropathies; LidoPAIN SP, a sterile prescription analgesic patch designed to provide sustained topical delivery of lidocaine to a post-surgical or post-traumatic sutured wound; and LidoPAIN BP, a prescription analgesic non-sterile patch designed to provide sustained topical delivery of lidocaine for the treatment of acute or recurrent lower back pain; and Azixa, a Phase II clinical trial product, for the treatment of cancer that has metastasized to the brain. In addition, it offers EpiCept MP/DP, an earlier-stage product candidate, which is a topical spray gel matrix, containing morphine and lidocaine for oral mucositis; LidoPAIN TV for the treatment of tinnitus; and LidoPAIN HM for the treatment of headache. It also develops EPC2407, a Phase I clinical trial product, for the treatment of patients with advanced solid tumors and lymphomas; EP2167, a pre-clinical stage product, a compound that induce apoptosis in cancer cells in multiple cell lines, including prostate, breast, colorectal, non-small cell lung and small cell lung cancers, and leukemia; and EP128504, an inducer of apoptosis for treatment of cancer in breast and colorectal cancer cells. The company has strategic alliances with DURECT Corporation; Endo Pharmaceuticals, Inc.; and Myriad Genetics, Inc. EpiCept was founded in 1993 and is based in Tarrytown, New York.


Gene Logic, Inc. provides drug discovery and development services to pharmaceutical and biotechnology companies worldwide. The company operates in three segments: Genomics and Toxicogenomics Services, Preclinical Contract Research Services, and Drug Repositioning and Selection Services. The Genomics and Toxicogenomics Services segment enables customers to discover and prioritize drug targets, identify biomarkers, and predict toxicity and provide insights into efficacy of specific compounds through the use of gene expression technologies, reference databases, and bioinformatics software and professional services. This segment comprises BioExpress System, ASCENTA System, data generation services, ToxExpress System, toxicogenomics Services, ToxShield Suite, and Genesis Enterprise System. The Preclinical Contract Research Services segment consists of in-vivo animal testing research studies and related laboratory services that are used to assess the safety and pharmacologic effects of compounds for customers. This segment offers general toxicology services, specialty toxicology services, and analytical laboratory services. The Drug Repositioning and Selection Services segment assists customers in identifying alternative indications for failed, stalled, or deprioritized compounds; expanding indications for marketed drugs; and prioritizing and identifying indications for compounds entering preclinical development. It offers its genomics and toxicogenomics services to pharmaceutical and biotechnology companies in North America, Japan, and Western Europe, as well as provides preclinical contract research services to pharmaceutical and biotechnology companies in North America and to United States government agencies. Gene Logic was incorporated in 1994 and is headquartered in Gaithersburg, Maryland.


Interleukin Genetics, Inc. focuses on developing, acquiring, and commercializing personalized health products for individuals to maintain their health through preventive measures. The company uses functional genomics to help in the development of risk assessment tests based on the genetic variations in people. It also develops and markets nutritional and OTCeutical products. Interleukin Genetics commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. The company sells its nutritional product brands, including Ginkoba, Ginsana, and Venastat through food, drug, and mass retailers. Its development programs focus on osteoporosis and weight management genetic risk assessment tests, as well as on its new proprietary OTCeuticals. Interleukin Genetics has a strategic alliance with the Alticor, Inc. to develop and market genetic risk assessment tests, and nutritional and skin care products; and a research agreement with Access Business Group LLC for development of genetic tests to guide consumers' selection of appropriate skin care products. It also has academic research collaborations with University of Sheffield, Tufts University, Harvard University, the Mayo Clinic, California Pacific Medical Center, Boston University, the University of Arkansas, Tongji Medical College, and Yonsei University. The company was founded in 1986 and is based in Waltham, Massachusetts.